The prevalence and clinical implication of rare germline deleterious alterations in Chinese patients with prostate cancer: A real-world multicenter study

Clin Transl Med. 2021 Oct;11(10):e527. doi: 10.1002/ctm2.527.

Authors

Xiaochen Fei¹, Liancheng Fan¹, Wei Chen², Wei Chen³, Yiming Gong¹, Xinxing Du¹, Yanqing Wang¹, Yinjie Zhu¹, Jiahua Pan¹, Fangqin Wang⁴, Wanbing Zhao⁴, Tongtong Liu⁴, Yining Yang⁴, Baijun Dong¹, Wei Xue¹

Affiliations

¹ Department of Urology, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.
² Department of Urology, The First Affiliated Hospital of Wenzhou Medical University, Zhejiang, China.
³ Department of Urology, Zhongshan Hospital, Shanghai Medical College, Fudan University, Shanghai, China.
⁴ GloriousMedTechnologyCo., Ltd, Shanghai, China.

No abstract available

Publication types

Letter
Multicenter Study
Research Support, Non-U.S. Gov't

MeSH terms

Aged
China / epidemiology
Germ-Line Mutation / genetics*
Humans
Male
Middle Aged
Prevalence
Prostatic Neoplasms / epidemiology*
Prostatic Neoplasms / genetics*